EUVIMEDEUVIMED entdecken
Crossref

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Ashwin Gupta, Nicholas Nosbisch, Ishan Agarwal, Anjali Patel, Sowmyanarayanan Thuppal, Chaitanya Mamillipalli, Jessi Prentice, Jaycob Avaylon, Ron Gallemore, Ramanath Bhandari

Re:GEN Open · 2022

DOI: 10.1089/regen.2021.0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Re:GEN Open, 2022. Verfasst von Ashwin Gupta und 9 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To determine the efficacy of brolucizumab in patients with aflibercept resistant neovascular age-related macular degeneration (AMD).

Methods

This case series retrospectively collected data from October 2019 to March 2020 of 13 patients detailing aflibercept-resistant AMD. Patients received at least three doses of 2 mg/0.05 mL aflibercept on a 4-week dosing schedule before switching to three doses of 6 mg/0.05 mL brolucizumab on a 4-week schedule. Central subfield thickness (CST) and visual acuity (VA) were measured before and after each drug’s administration.

Results

The mean baseline VA was logMAR 0.85 [0.65], which worsened to logMAR 0.86 [0.53] after aflibercept. The VA improved to a mean of logMAR 0.70 [0.44] with brolucizumab, but this fell short of significance (0.70, 95% CI: 0.40-1.00; P = 0.16). The mean baseline CST was 354.62 [93.79] μm, and it worsened to 369.31 [116.61] μm after aflibercept administration. Following the brolucizumab treatment, the mean CST significantly improved to 290.46 [89.84] μm (290.46, 95% CI: 228.21-352.72; P = 0.03). After brolucizumab use, there was no observed occlusive retinal vasculitis in this case series.

Conclusion

Brolucizumab significantly improved CST, but the VA improvement fell short of significance. Three individuals experienced inflammation following brolucizumab use, but there were no observed occlusive retinal vasculitis. While brolucizumab may not be the first option to treat AMD, it holds value for patients who have been unresponsive to other anti-vascular endothelial growth factor agents.

Zitieren

APA

Gupta, A., Nosbisch, N., Agarwal, I., Patel, A., Thuppal, S., Mamillipalli, C., Prentice, J., Avaylon, J., Gallemore, R., & Bhandari, R. (2022). Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Re:GEN Open. https://doi.org/10.1089/regen.2021.0035

Vancouver

Gupta A, Nosbisch N, Agarwal I, Patel A, Thuppal S, Mamillipalli C, et al. Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Re:GEN Open. 2022. doi:10.1089/regen.2021.0035

BibTeX
@article{Gupta2022,
  author = {Gupta, Ashwin and Nosbisch, Nicholas and Agarwal, Ishan and Patel, Anjali and Thuppal, Sowmyanarayanan and Mamillipalli, Chaitanya and Prentice, Jessi and Avaylon, Jaycob and Gallemore, Ron and Bhandari, Ramanath},
  title = {Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration},
  journal = {Re:GEN Open},
  year = {2022},
  doi = {10.1089/regen.2021.0035}
}
Kostenlos starten →